Search PubMed⌕ Search

Biomedical subjects

T Naoe

Publications and source records attributed to T Naoe.

At least 181 records · Page 10Linked to original sources
PubMed1987

Production of chimeric protein coded by the fused viral H-ras and human N-ras genes in Escherichia coli.

A new method for the production of a chimeric protein of two related genes has been developed. The nucleotide sequences of the region from the N terminus to the 86th amino acid (aa) residue of human N-ras and of the Harvey sarcoma virus (Ha-MuSV) H-ras are 80% homologous. We isolated the DNA fragment encoding the N-terminal portion up to the 70th aa residue from plasmid pH-1 which encodes the total genome of Ha-MuSV, and the DNA fragment encoding the C-terminal portion from the 40th aa to the C terminus from plasmid p6a1 which includes the human N-ras cDNA but lacks the N-terminal portion. After partial digestion of both fragments with phage lambda exonuclease, which creates 3'-protruding ends, a hybrid was formed between 73% homologous single-stranded DNA portions at the 3' ends of both fragments. The hybrid was recloned on pBR322 after repairing with Escherichia coli DNA polymerase I and DNA ligase. The chimeric v-H/N-ras gene composed of the N-terminal portion of v-H-ras gene and the remaining region of N-ras gene was inserted into an expression vector containing two tandem trp promoters and a terminator, and expressed in E. coli. The chimeric protein was found to accumulate to approx. 10% of total cellular proteins.

Amino Acid Sequence↗
PubMed1986

[Clinical trial of bestrabucil (KM 2210) in hematopoietic malignancies].

Thirteen patients with hematological neoplasms were treated with Bestrabucil (100 mg/day po, total dose 700-9,900 mg), which is the benzoate of an estradiol-chlorambucil conjugate. The diseases from which they suffered consisted of T-cell leukemia (3), lymphoma (3), myeloma (5) and essential thrombocytosis (2). Although this drug was less effective against myeloma, the other diseases were more or less relieved with this medication. That is, Bestrabucil was effective in all three patients with T-cell leukemia, both with essential thrombocytosis and two of the three with lymphoma. It is most interesting that adult T-cell leukemia (ATL) cells decreased remarkably with Bestrabucil, along with the disappearance of several symptoms (bone pain, hypercalcemia etc.). The main side effects during this medication were mammary pain (eight of 13 patients, 62%), anorexia (five of 13 patients, 39%) and loss of libido (three of 13 patients, 23%), but neither severe myelosuppression nor hepatorenal dysfunction was induced.

Aged↗
PubMed1985

Production and analysis of HH 10 monoclonal antibodies reactive to immature hematopoietic cells and their use for monitoring acute leukemia cells.

A clone of murine monoclonal antibody HH 10 (IgM) was raised by fusing NS-1 myeloma cells and spleen cells of a mouse hyperimmunized with acute promyelocytic leukemia cells. Serological analysis by means of immune adherence assays showed that HH 10 reacts with immature hematopoietic cells including thymocytes and myeloid precursor cells (defined as colony-forming units in culture assays). The antibodies were not reactive to either peripheral blood cells or bone marrow cells obtained from normal individuals. Lymphoid blasts induced with phytohemagglutinin, pokeweed mitogen, or concanavalin A were also non-reactive, and all non-hematopoietic cultured cells examined were also negative. The antibodies were, however, reactive to leukemia cells in 67 cases out of 91 cases (74%) of acute leukemia. In patients with acute lymphoblastic leukemia, 43 out of 52 cases (83%) were positive and, in particular, all of 12 T-cell-type acute leukemias were reactive to HH 10. Comparison of percent HH 10 positive cells in the bone marrow of patients with acute leukemia with the results of cytological studies showed a good correlation. Analysis of sequentially collected bone marrow cells of acute leukemia patients using HH 10 revealed its usefulness for monitoring leukemia cells.

Acute Disease↗
PubMed1983

[Human monoclonal antibodies with human-mouse hybridomas].

Our trial to produce human monoclonal antibodies with human-mouse hybridomas is described. Human spleen cells, in comparison with peripheral blood lymphocytes, bone marrow cells and lymphnode lymphocytes, seem to be the best partner to fuse with myeloma line NS-1 to obtain hybridomas. About sixty percent of hybridomas derived from human spleen cells at first produce human Ig which in most cases belong to either IgG or IgM. Fifty percent of hybridomas which had initially produced human Ig continued to do so after 4 months. One of the clones of human monoclonal antibodies reacted with a cell surface antigen expressed on three out of 5 B cell lines, 14 out of 38 Epstein-Barr virus transformed B cell lines and null cell type lymphocytic leukemia cells obtained from one patient out of 34 tested. Other normal or malignant cells, hematopoietic or nonhematopoietic cells examined were negative. The antigen does not seem to be related to EBNA, early antigen and VCA of EB virus, or certain haplotype specificity of HLA-A, B, C, and DR loci. Reports by others on production of monoclonal antibodies with similar approaches were also reviewed.

Animals↗